BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ricklin D, Lambris JD. Progress and Trends in Complement Therapeutics. Adv Exp Med Biol 2013;735:1-22. [PMID: 22990692 DOI: 10.1007/978-1-4614-4118-2_1] [Cited by in Crossref: 93] [Cited by in F6Publishing: 78] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Michelfelder S, Fischer F, Wäldin A, Hörle KV, Pohl M, Parsons J, Reski R, Decker EL, Zipfel PF, Skerka C, Häffner K. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential. J Am Soc Nephrol 2018;29:1141-53. [PMID: 29335241 DOI: 10.1681/ASN.2017070738] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
2 Tong HH, Lambert G, Li YX, Thurman JM, Stahl GL, Douthitt K, Clancy C, He Y, Bowman AS. Deletion of the complement C5a receptor alleviates the severity of acute pneumococcal otitis media following influenza A virus infection in mice. PLoS One 2014;9:e95160. [PMID: 24740152 DOI: 10.1371/journal.pone.0095160] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
3 Kleczko EK, Kwak JW, Schenk EL, Nemenoff RA. Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer. Front Immunol 2019;10:954. [PMID: 31134065 DOI: 10.3389/fimmu.2019.00954] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
4 Garcia BL, Zwarthoff SA, Rooijakkers SH, Geisbrecht BV. Novel Evasion Mechanisms of the Classical Complement Pathway. J Immunol 2016;197:2051-60. [PMID: 27591336 DOI: 10.4049/jimmunol.1600863] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
5 Ghosh P, Sahoo R, Vaidya A, Chorev M, Halperin JA. Role of complement and complement regulatory proteins in the complications of diabetes. Endocr Rev. 2015;36:272-288. [PMID: 25859860 DOI: 10.1210/er.2014-1099] [Cited by in Crossref: 74] [Cited by in F6Publishing: 68] [Article Influence: 10.6] [Reference Citation Analysis]
6 Risitano AM. Current and Future Pharmacologic Complement Inhibitors. Hematology/Oncology Clinics of North America 2015;29:561-82. [DOI: 10.1016/j.hoc.2015.01.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
7 Shim K, Begum R, Yang C, Wang H. Complement activation in obesity, insulin resistance, and type 2 diabetes mellitus. World J Diabetes 2020;11:1-12. [PMID: 31938469 DOI: 10.4239/wjd.v11.i1.1] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 25] [Article Influence: 15.5] [Reference Citation Analysis]
8 Kim H, Conway EM. Platelets and Complement Cross-Talk in Early Atherogenesis. Front Cardiovasc Med 2019;6:131. [PMID: 31555668 DOI: 10.3389/fcvm.2019.00131] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
9 Ferreira VP, Fazito Vale V, Pangburn MK, Abdeladhim M, Mendes-Sousa AF, Coutinho-Abreu IV, Rasouli M, Brandt EA, Meneses C, Lima KF, Nascimento Araújo R, Pereira MH, Kotsyfakis M, Oliveira F, Kamhawi S, Ribeiro JM, Gontijo NF, Collin N, Valenzuela JG. SALO, a novel classical pathway complement inhibitor from saliva of the sand fly Lutzomyia longipalpis. Sci Rep 2016;6:19300. [PMID: 26758086 DOI: 10.1038/srep19300] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
10 Stites E, Le Quintrec M, Thurman JM. The Complement System and Antibody-Mediated Transplant Rejection. J Immunol 2015;195:5525-31. [PMID: 26637661 DOI: 10.4049/jimmunol.1501686] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 5.5] [Reference Citation Analysis]
11 Reuter S, Mrowka R. The complement system in kidney diseases. Acta Physiol (Oxf) 2017;220:398-401. [PMID: 28636786 DOI: 10.1111/apha.12909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Michelfelder S, Parsons J, Bohlender LL, Hoernstein SNW, Niederkrüger H, Busch A, Krieghoff N, Koch J, Fode B, Schaaf A, Frischmuth T, Pohl M, Zipfel PF, Reski R, Decker EL, Häffner K. Moss-Produced, Glycosylation-Optimized Human Factor H for Therapeutic Application in Complement Disorders. J Am Soc Nephrol 2017;28:1462-74. [PMID: 27932477 DOI: 10.1681/ASN.2015070745] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
13 Khan MA, Assiri AM, Broering DC. Complement mediators: key regulators of airway tissue remodeling in asthma. J Transl Med 2015;13:272. [PMID: 26289385 DOI: 10.1186/s12967-015-0565-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
14 Harris CL. Expanding horizons in complement drug discovery: challenges and emerging strategies. Semin Immunopathol 2018;40:125-40. [PMID: 28986638 DOI: 10.1007/s00281-017-0655-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
15 Frémeaux-Bacchi V, Legendre CM. The emerging role of complement inhibitors in transplantation. Kidney Int 2015;88:967-73. [PMID: 26376132 DOI: 10.1038/ki.2015.253] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
16 Frazer-Abel A, Sepiashvili L, Mbughuni MM, Willrich MA. Overview of Laboratory Testing and Clinical Presentations of Complement Deficiencies and Dysregulation. Adv Clin Chem 2016;77:1-75. [PMID: 27717414 DOI: 10.1016/bs.acc.2016.06.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
17 Peterson SL, Anderson AJ. Complement and spinal cord injury: traditional and non-traditional aspects of complement cascade function in the injured spinal cord microenvironment. Exp Neurol 2014;258:35-47. [PMID: 25017886 DOI: 10.1016/j.expneurol.2014.04.028] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
18 Paderi J, Prestwich GD, Panitch A, Boone T, Stuart K. Glycan Therapeutics: Resurrecting an Almost Pharma‐Forgotten Drug Class. Adv Therap 2018;1:1800082. [DOI: 10.1002/adtp.201800082] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
19 Durigutto P, Sblattero D, Biffi S, De Maso L, Garrovo C, Baj G, Colombo F, Fischetti F, Di Naro AF, Tedesco F, Macor P. Targeted Delivery of Neutralizing Anti-C5 Antibody to Renal Endothelium Prevents Complement-Dependent Tissue Damage. Front Immunol 2017;8:1093. [PMID: 28932227 DOI: 10.3389/fimmu.2017.01093] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
20 Mastellos DC, Yancopoulou D, Kokkinos P, Huber-lang M, Hajishengallis G, Biglarnia AR, Lupu F, Nilsson B, Risitano AM, Ricklin D, Lambris JD. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur J Clin Invest 2015;45:423-40. [DOI: 10.1111/eci.12419] [Cited by in Crossref: 122] [Cited by in F6Publishing: 115] [Article Influence: 17.4] [Reference Citation Analysis]
21 Woehl JL, Stapels DAC, Garcia BL, Ramyar KX, Keightley A, Ruyken M, Syriga M, Sfyroera G, Weber AB, Zolkiewski M, Ricklin D, Lambris JD, Rooijakkers SHM, Geisbrecht BV. The extracellular adherence protein from Staphylococcus aureus inhibits the classical and lectin pathways of complement by blocking formation of the C3 proconvertase. J Immunol 2014;193:6161-71. [PMID: 25381436 DOI: 10.4049/jimmunol.1401600] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
22 Moghimi SM. Complement Propriety and Conspiracy in Nanomedicine: Perspective and a Hypothesis. Nucleic Acid Therapeutics 2016;26:67-72. [DOI: 10.1089/nat.2015.0587] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
23 Mohamed MME, Nicklin AD, Stover CM. The Value of Targeting Complement Components in Asthma. Medicina (Kaunas) 2020;56:E405. [PMID: 32806638 DOI: 10.3390/medicina56080405] [Reference Citation Analysis]
24 Regal JF, Gilbert JS, Burwick RM. The complement system and adverse pregnancy outcomes. Mol Immunol 2015;67:56-70. [PMID: 25802092 DOI: 10.1016/j.molimm.2015.02.030] [Cited by in Crossref: 83] [Cited by in F6Publishing: 75] [Article Influence: 11.9] [Reference Citation Analysis]
25 Ricklin D, Lambris JD. Therapeutic control of complement activation at the level of the central component C3. Immunobiology 2016;221:740-6. [PMID: 26101137 DOI: 10.1016/j.imbio.2015.06.012] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
26 He Y, Scholes MA, Wiet GJ, Li Q, Clancy C, Tong HH. Complement activation in pediatric patients with recurrent acute otitis media. Int J Pediatr Otorhinolaryngol 2013;77:911-7. [PMID: 23537925 DOI: 10.1016/j.ijporl.2013.03.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
27 Phuan PW, Zhang H, Asavapanumas N, Leviten M, Rosenthal A, Tradtrantip L, Verkman AS. C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica. Acta Neuropathol 2013;125:829-40. [PMID: 23677375 DOI: 10.1007/s00401-013-1128-3] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 5.6] [Reference Citation Analysis]
28 Charchaflieh J, Rushbrook J, Worah S, Zhang M. Activated Complement Factors as Disease Markers for Sepsis. Dis Markers 2015;2015:382463. [PMID: 26420913 DOI: 10.1155/2015/382463] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
29 Mastellos DC, Ricklin D, Yancopoulou D, Risitano A, Lambris JD. Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. Expert Rev Hematol 2014;7:583-98. [PMID: 25213458 DOI: 10.1586/17474086.2014.953926] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
30 Yang CY, Phillips JG, Stuckey JA, Bai L, Sun H, Delproposto J, Brown WC, Chinnaswamy K. Buried Hydrogen Bond Interactions Contribute to the High Potency of Complement Factor D Inhibitors. ACS Med Chem Lett 2016;7:1092-6. [PMID: 27994744 DOI: 10.1021/acsmedchemlett.6b00299] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
31 Weitoft M, Müller C, Åhrman E, Bjermer L, Hoffmann HJ, Erjefält J, Westergren-Thorsson G. Comparison of Normal and Metaplastic Epithelium in Patients with Stable versus Persistently Symptomatic Severe Asthma Using Laser-Capture Microdissection and Data-Independent Acquisition-Mass Spectrometry. Am J Pathol 2019;189:2358-65. [PMID: 31761031 DOI: 10.1016/j.ajpath.2019.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Conway EM. Complement-coagulation connections. Blood Coagul Fibrinolysis 2018;29:243-51. [PMID: 29517503 DOI: 10.1097/MBC.0000000000000720] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 5.8] [Reference Citation Analysis]
33 Chinchilla B, Foltopoulou P, Fernandez-Godino R. Tick-over-mediated complement activation is sufficient to cause basal deposit formation in cell-based models of macular degeneration. J Pathol 2021. [PMID: 34155630 DOI: 10.1002/path.5747] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Karpman D, Ståhl AL, Arvidsson I, Johansson K, Loos S, Tati R, Békássy Z, Kristoffersson AC, Mossberg M, Kahn R. Complement Interactions with Blood Cells, Endothelial Cells and Microvesicles in Thrombotic and Inflammatory Conditions. Adv Exp Med Biol 2015;865:19-42. [PMID: 26306441 DOI: 10.1007/978-3-319-18603-0_2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
35 Mastellos DC, Reis ES, Yancopoulou D, Hajishengallis G, Ricklin D, Lambris JD. From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Immunobiology 2016;221:1046-57. [PMID: 27353192 DOI: 10.1016/j.imbio.2016.06.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
36 Roumenina LT, Zuber J, Frémeaux-Bacchi V. Physiological and therapeutic complement regulators in kidney transplantation. Curr Opin Organ Transplant 2013;18:421-9. [PMID: 23838647 DOI: 10.1097/MOT.0b013e32836370ce] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
37 Holers VM. Targeting mechanisms at sites of complement activation for imaging and therapy. Immunobiology 2016;221:726-32. [PMID: 25979851 DOI: 10.1016/j.imbio.2015.04.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
38 Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol. 2013;190:3839-3847. [PMID: 23564578 DOI: 10.4049/jimmunol.1203200] [Cited by in Crossref: 162] [Cited by in F6Publishing: 145] [Article Influence: 18.0] [Reference Citation Analysis]
39 Rogers LM, Veeramani S, Weiner GJ. Complement in monoclonal antibody therapy of cancer. Immunol Res 2014;59:203-10. [PMID: 24906530 DOI: 10.1007/s12026-014-8542-z] [Cited by in Crossref: 66] [Cited by in F6Publishing: 56] [Article Influence: 9.4] [Reference Citation Analysis]
40 Foley JH, Conway EM. Basic weapons to degrade C3a and C5a. J Thromb Haemost 2018;16:987-90. [PMID: 29518284 DOI: 10.1111/jth.13999] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
41 Frazer-Abel A. The effect on the immunology laboratory of the expansion in complement therapeutics. J Immunol Methods 2018;461:30-6. [PMID: 30092178 DOI: 10.1016/j.jim.2018.08.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
42 Ma Y, Liu Y, Zhang Z, Yang GY. Significance of Complement System in Ischemic Stroke: A Comprehensive Review. Aging Dis 2019;10:429-62. [PMID: 31011487 DOI: 10.14336/AD.2019.0119] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 11.7] [Reference Citation Analysis]
43 DeAngelis RA, Reis ES, Ricklin D, Lambris JD. Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis. Immunobiology 2012;217:1097-105. [PMID: 22964235 DOI: 10.1016/j.imbio.2012.07.012] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
44 Mendes-Sousa AF, Queiroz DC, Vale VF, Ribeiro JM, Valenzuela JG, Gontijo NF, Andersen JF. An Inhibitor of the Alternative Pathway of Complement in Saliva of New World Anopheline Mosquitoes. J Immunol 2016;197:599-610. [PMID: 27307559 DOI: 10.4049/jimmunol.1600020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
45 Bekker P, Dairaghi D, Seitz L, Leleti M, Wang Y, Ertl L, Baumgart T, Shugarts S, Lohr L, Dang T, Miao S, Zeng Y, Fan P, Zhang P, Johnson D, Powers J, Jaen J, Charo I, Schall TJ. Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study. PLoS One 2016;11:e0164646. [PMID: 27768695 DOI: 10.1371/journal.pone.0164646] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 8.7] [Reference Citation Analysis]
46 Muldur S, Vadysirisack DD, Ragunathan S, Tang Y, Ricardo A, Sayegh CE, Irimia D. Human Neutrophils Respond to Complement Activation and Inhibition in Microfluidic Devices. Front Immunol 2021;12:777932. [PMID: 34899737 DOI: 10.3389/fimmu.2021.777932] [Reference Citation Analysis]
47 Hourcade DE, Akk AM, Mitchell LM, Zhou HF, Hauhart R, Pham CT. Anti-complement activity of the Ixodes scapularis salivary protein Salp20. Mol Immunol 2016;69:62-9. [PMID: 26675068 DOI: 10.1016/j.molimm.2015.11.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
48 Thurman JM, Frazer-Abel A, Holers VM. The Evolving Landscape for Complement Therapeutics in Rheumatic and Autoimmune Diseases. Arthritis Rheumatol 2017;69:2102-13. [PMID: 28732131 DOI: 10.1002/art.40219] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
49 Ricklin D, Lambris JD. New milestones ahead in complement-targeted therapy. Semin Immunol 2016;28:208-22. [PMID: 27321574 DOI: 10.1016/j.smim.2016.06.001] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 10.7] [Reference Citation Analysis]
50 Hajishengallis G, Abe T, Maekawa T, Hajishengallis E, Lambris JD. Role of complement in host-microbe homeostasis of the periodontium. Semin Immunol 2013;25:65-72. [PMID: 23684627 DOI: 10.1016/j.smim.2013.04.004] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 5.9] [Reference Citation Analysis]
51 Papadopoulos MC, Bennett JL, Verkman AS. Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol. 2014;10:493-506. [PMID: 25112508 DOI: 10.1038/nrneurol.2014.141] [Cited by in Crossref: 148] [Cited by in F6Publishing: 135] [Article Influence: 18.5] [Reference Citation Analysis]
52 Sandahl TD, Kelsen J, Dige A, Dahlerup JF, Agnholt J, Hvas CL, Thiel S. The lectin pathway of the complement system is downregulated in Crohn's disease patients who respond to anti-TNF-α therapy. J Crohns Colitis 2014;8:521-8. [PMID: 24291022 DOI: 10.1016/j.crohns.2013.11.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
53 Risitano AM, Marotta S. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future. Semin Immunol 2016;28:223-40. [PMID: 27346521 DOI: 10.1016/j.smim.2016.05.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
54 Prohászka Z, Nilsson B, Frazer-Abel A, Kirschfink M. Complement analysis 2016: Clinical indications, laboratory diagnostics and quality control. Immunobiology 2016;221:1247-58. [PMID: 27475991 DOI: 10.1016/j.imbio.2016.06.008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 7.3] [Reference Citation Analysis]
55 Mastellos DC, Ricklin D, Hajishengallis E, Hajishengallis G, Lambris JD. Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention. Mol Oral Microbiol 2016;31:3-17. [PMID: 26332138 DOI: 10.1111/omi.12129] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
56 Haapasalo K, Wollman AJM, de Haas CJC, van Kessel KPM, van Strijp JAG, Leake MC. Staphylococcus aureus toxin LukSF dissociates from its membrane receptor target to enable renewed ligand sequestration. FASEB J 2019;33:3807-24. [PMID: 30509126 DOI: 10.1096/fj.201801910R] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
57 Zelek WM, Harris CL, Morgan BP. Extracting the barbs from complement assays: Identification and optimisation of a safe substitute for traditional buffers. Immunobiology 2018;223:744-9. [PMID: 30033110 DOI: 10.1016/j.imbio.2018.07.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
58 Vogel C, Fritzinger D, Gorsuch B, Stahl G. Complement depletion with humanised cobra venom factor: Efficacy in preclinical models of vascular diseases. Thromb Haemost 2017;113:548-52. [DOI: 10.1160/th14-04-0300] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
59 Syed S, Viazmina L, Mager R, Meri S, Haapasalo K. Streptococci and the complement system: interplay during infection, inflammation and autoimmunity. FEBS Lett 2020;594:2570-85. [PMID: 32594520 DOI: 10.1002/1873-3468.13872] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
60 Poppelaars F, Faria B, Gaya da Costa M, Franssen CFM, van Son WJ, Berger SP, Daha MR, Seelen MA. The Complement System in Dialysis: A Forgotten Story? Front Immunol 2018;9:71. [PMID: 29422906 DOI: 10.3389/fimmu.2018.00071] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
61 Nagi-Miura N, Okuzaki D, Torigata K, Sakurai MA, Ito A, Ohno N, Nojima H. CAWS administration increases the expression of interferon γ and complement factors that lead to severe vasculitis in DBA/2 mice. BMC Immunol 2013;14:44. [PMID: 24063402 DOI: 10.1186/1471-2172-14-44] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
62 Wang Y, Guo W, Xie S, Liu Y, Xu D, Chen G, Xu Y. Multi-omics analysis of brain tissue metabolome and proteome reveals the protective effect of gross saponins of Tribulus terrestris L. fruit against ischemic stroke in rat. J Ethnopharmacol 2021;278:114280. [PMID: 34082014 DOI: 10.1016/j.jep.2021.114280] [Reference Citation Analysis]
63 Hinson SR, Lennon VA, Pittock SJ. Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders. Handb Clin Neurol. 2016;133:377-403. [PMID: 27112688 DOI: 10.1016/b978-0-444-63432-0.00021-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 7.2] [Reference Citation Analysis]
64 Morgan BP. The role of complement in neurological and neuropsychiatric diseases. Expert Rev Clin Immunol 2015;11:1109-19. [PMID: 26389851 DOI: 10.1586/1744666X.2015.1074039] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
65 Zhu W, Wang Z, Hu S, Gong Y, Liu Y, Song H, Ding X, Fu Y, Yan Y. Human C5-specific single-chain variable fragment ameliorates brain injury in a model of NMOSD. Neurol Neuroimmunol Neuroinflamm 2019;6:e561. [PMID: 31044149 DOI: 10.1212/NXI.0000000000000561] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
66 Long Z, Du Y, Li H, Han B. CR1 gene polymorphisms in Chinese patients with paroxysmal nocturnal hemoglobinuria. Gene 2018;659:149-54. [DOI: 10.1016/j.gene.2018.03.037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
67 Huber-lang M, Gebhard F, Schmidt CQ, Palmer A, Denk S, Wiegner R. Complement therapeutic strategies in trauma, hemorrhagic shock and systemic inflammation – closing Pandora’s box? Seminars in Immunology 2016;28:278-84. [DOI: 10.1016/j.smim.2016.04.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
68 De Vriese AS, Sethi S, Van Praet J, Nath KA, Fervenza FC. Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach. J Am Soc Nephrol. 2015;26:2917-2929. [PMID: 26185203 DOI: 10.1681/asn.2015020184] [Cited by in Crossref: 53] [Cited by in F6Publishing: 27] [Article Influence: 7.6] [Reference Citation Analysis]
69 Conway EM. Reincarnation of ancient links between coagulation and complement. J Thromb Haemost 2015;13 Suppl 1:S121-32. [PMID: 26149013 DOI: 10.1111/jth.12950] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 10.0] [Reference Citation Analysis]
70 Holers VM, Tomlinson S, Kulik L, Atkinson C, Rohrer B, Banda N, Thurman JM. New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities. Semin Immunol 2016;28:260-7. [PMID: 27282113 DOI: 10.1016/j.smim.2016.05.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
71 Ricklin D. Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy. Immunobiology 2012;217:1057-66. [PMID: 22964231 DOI: 10.1016/j.imbio.2012.07.016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
72 Volk AL, Hu FJ, Berglund MM, Nordling E, Strömberg P, Uhlen M, Rockberg J. Stratification of responders towards eculizumab using a structural epitope mapping strategy. Sci Rep 2016;6:31365. [PMID: 27509843 DOI: 10.1038/srep31365] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
73 Sagar A, Dai W, Minot M, LeCover R, Varner JD. Reduced order modeling and analysis of the human complement system. PLoS One 2017;12:e0187373. [PMID: 29155837 DOI: 10.1371/journal.pone.0187373] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
74 Cheng TH, Puskarich M, Li X, Fang Z, Xu F, Chen Y, Jiang XC, Worah S, Jones AE, Zhang M. Circulating Complement C3-Alpha Chain Levels Predict Survival of Septic Shock Patients. Shock 2020;54:190-7. [PMID: 31880756 DOI: 10.1097/SHK.0000000000001502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
75 Poppelaars F, Seelen MA. Complement-mediated inflammation and injury in brain dead organ donors. Mol Immunol 2017;84:77-83. [PMID: 27989433 DOI: 10.1016/j.molimm.2016.11.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
76 Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol 2013;190:3831-8. [PMID: 23564577 DOI: 10.4049/jimmunol.1203487] [Cited by in Crossref: 288] [Cited by in F6Publishing: 276] [Article Influence: 32.0] [Reference Citation Analysis]
77 Lua WH, Ling WL, Yeo JY, Poh JJ, Lane DP, Gan SK. The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-binding. Sci Rep 2018;8:718. [PMID: 29335579 DOI: 10.1038/s41598-017-18892-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
78 Thurman JM, Le Quintrec M. Targeting the complement cascade: novel treatments coming down the pike. Kidney Int. 2016;90:746-752. [PMID: 27325183 DOI: 10.1016/j.kint.2016.04.018] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
79 Zhang L, Qiu W, Crooke S, Li Y, Abid A, Xu B, Finn MG, Lin F. Development of Autologous C5 Vaccine Nanoparticles to Reduce Intravascular Hemolysis in Vivo. ACS Chem Biol 2017;12:539-47. [PMID: 28045484 DOI: 10.1021/acschembio.6b00994] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
80 Vogel C, Finnegan PW, Fritzinger DC. Humanized cobra venom factor: Structure, activity, and therapeutic efficacy in preclinical disease models. Molecular Immunology 2014;61:191-203. [DOI: 10.1016/j.molimm.2014.06.035] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
81 Yatime L, Maasch C, Hoehlig K, Klussmann S, Andersen GR, Vater A. Structural basis for the targeting of complement anaphylatoxin C5a using a mixed L-RNA/L-DNA aptamer. Nat Commun 2015;6:6481. [PMID: 25901944 DOI: 10.1038/ncomms7481] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 6.1] [Reference Citation Analysis]